Fulcrum Therapeutics (FULC) Shares Outstanding (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Shares Outstanding (Entity) for 9 consecutive years, with $76.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Shares Outstanding (Entity) rose 41.05% year-over-year to $76.3 million; the TTM figure through Jun 2026 stood at $76.3 million (up 41.05% YoY), while the FY2025 annual figure was $63355.0, up 2.21% from the prior year.
• Shares Outstanding (Entity) grew to $76.3 million in Q2 2026 per FULC's latest filing, from $66.6 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $76.3 million in Q2 2026 and bottomed at $40890.0 in Q2 2022.
• Historically, Shares Outstanding (Entity) has averaged $25.7 million across 5 years, with a median of $62669.5 in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) soared 129013.31% — and 2023, when it tumbled 99.85%.
• Fulcrum Therapeutics' Shares Outstanding (Entity) stood at $44991.0 in 2022, then soared by 36.27% to $61310.0 in 2023, then climbed by 1.1% to $61984.0 in 2024, then increased by 2.21% to $63355.0 in 2025, then jumped by 120328.15% to $76.3 million in 2026.
• Business Quant data shows FULC's Shares Outstanding (Entity) at $76.3 million in Q2 2026, $66.6 million in Q1 2026, and $63355.0 in Q4 2025.